Clostridium butyricum (Qingdao Eastsea Pharmaceuticals)

酪酸梭菌活菌（青岛东海药业）

Report date: 2022/09/27 17:03:22

Base Information

Drug NameClostridium butyricum (Qingdao Eastsea Pharmaceuticals)
Drug Alias Name阿泰宁
ClassificationNatural product/Extract > Microbial extractBiologics > Live Biotherapeutic
Mechanisms of ActionGastrointestinal microbiome modulatorsBacteria replacements
TargetsNot applicable
Therapy Area/IndicationsDyspepsiaDiarrheaIrritable Bowel Syndrome +[5] 
Global Approved IndicationsDyspepsiaDiarrheaIrritable Bowel Syndrome +[5] 
Approved Indications in ChinaDyspepsiaDiarrheaIrritable Bowel Syndrome +[5] 
Original Approved Country/TerritoryMainland China
Original Approved Date2004/11/26
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQingdao Eastsea Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQingdao Eastsea Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDyspepsiaDiarrheaIrritable Bowel Syndrome +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeA07FA
Related LinksN/A